Coleman Mark
SEC CIK 1658379 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| AXSM | Axsome Therapeutics, Inc. | Dir | 30.4K | $250.6K | $12.33M | 19 | 2021-11-18 | 2026-06-10 |
Most active insiders at AXSM, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | TABUTEAU HERRIOT | CEO, Dir, 10% | — | $103.22M |
| 2 | Pizzie Nick | CFO | — | $10.18M |
| 3 | Jacobson Mark L. | COO | — | $8.90M |
| 4 | Coleman Mark | Dir | — | $8.21M |
| 5 | Saad Mark E | Dir | — | $6.21M |
| 6 | Maizel Ari | Chief Commercial Off | — | $2.75M |
| 7 | Mahony Susan | Dir | — | $145.0K |
| 8 | JEFFS ROGER | Dir | — | $141.7K |
Transactions 19
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-10 21:49 | 2026-06-08 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | M - OptEx | — | +1,429 | 31.0K | +5% | — |
| DT | 2026-06-10 21:49 | 2026-06-10 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | S - Sale+OE | $249.00 | -643 | 30.4K | -2% | -$160.1K |
| MT | 2026-06-02 19:00 | 2026-05-29+ | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | S - Sale | $229.20 | -17.5K | 29.6K | -37% | -$4.02M |
| T | 2026-02-27 | 2026-02-26 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | S - Sale | $161.11 | -25.0K | 47.1K | -35% | -$4.03M |
| D | 2026-02-25 | 2026-02-23 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | M - OptEx | $4.95 | +6,250 | 72.1K | +9% | +$30.9K |
| D | 2026-02-23 | 2026-02-20 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | M - OptEx | $4.95 | +12.5K | 65.9K | +23% | +$61.8K |
| D | 2026-02-10 | 2026-02-10 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | M - OptEx | $8.02 | +5,193 | 53.4K | +11% | +$41.6K |
| M | 2025-09-09 | 2025-09-08 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | P - Purchase | $127.28 | +1,575 | 47.4K | +3% | +$200.5K |
| MT | 2025-05-29 | 2025-05-27+ | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | S - Sale | $104.45 | -7,500 | 46.6K | -14% | -$783.4K |
| 2025-05-20 | 2025-05-20 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | S - Sale | $107.49 | -3,000 | 54.1K | -5% | -$322.5K | |
| D | 2025-01-06 | 2025-01-03 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | M - OptEx | $9.00 | +9,127 | 57.1K | +19% | +$82.1K |
| D | 2024-11-20 | 2024-11-19 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | M - OptEx | $5.94 | +33.4K | 48.0K | +229% | +$198.5K |
| MT | 2024-05-29 | 2024-05-28+ | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | S - Sale | $75.18 | -10.5K | 14.6K | -42% | -$789.1K |
| DI | 2023-09-15 | 2023-09-15 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | S - Sale+OE | $75.18 | -18.6K | 403.9K | -4% | -$1.40M |
| D | 2023-09-15 | 2023-09-15 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | M - OptEx | $3.67 | +11.0K | 36.1K | +44% | +$40.4K |
| D | 2023-09-15 | 2023-09-15 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | S - Sale+OE | $75.19 | -11.0K | 25.1K | -31% | -$828.3K |
| D | 2023-01-04 | 2023-01-03 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | M - OptEx | $1.30 | +17.5K | 25.1K | +230% | +$22.8K |
| D | 2022-03-17 | 2022-03-15 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | M - OptEx | $1.30 | +3,496 | 7,596 | +85% | +$4,545 |
| MI | 2021-11-22 | 2021-11-18 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | P - Purchase | $35.09 | +1,430 | 421.4K | +0.3% | +$50.2K |
Purchase Sale Sale after option exercise All abbreviations